Drug Patents owned by Bristol Myers Squibb

1. List of Eliquis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6967208 BRISTOL MYERS SQUIBB Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945 BRISTOL MYERS SQUIBB Apixaban formulations
Feb, 2031

(8 years from now)

Drugs and Companies using APIXABAN ingredient

Market Authorisation Date: 28 December, 2012

Treatment: Prophylaxis of deep vein thrombosis and pulmonary embolism; Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Reduce the risk of recurrent deep vein thrombosis (dvt); Treatment of deep vein thrombosis (dvt); Reduce the risk of recurrent pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Reducing the risk of stroke; Prophylaxis of pulmonary embolism

Dosage: TABLET;ORAL

How can I launch a generic of ELIQUIS before it's patent expiration?
More Information on Dosage

2. List of Sprycel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491725 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680103 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Feb, 2025

(2 years from now)

US8680103

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Aug, 2025

(2 years from now)

US7491725

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Sep, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2025
Pediatric Exclusivity (PED) May 9, 2025

Drugs and Companies using DASATINIB ingredient

Market Authorisation Date: 28 June, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SPRYCEL before it's patent expiration?
More Information on Dosage

3. List of Zerit Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7135465 BRISTOL MYERS SQUIBB Sustained release beadlets containing stavudine
Feb, 2023

(14 days from now)

US7135465

(Pediatric)

BRISTOL MYERS SQUIBB Sustained release beadlets containing stavudine
Aug, 2023

(6 months from now)

Drugs and Companies using STAVUDINE ingredient

Market Authorisation Date: 31 December, 2002

Treatment: Method for treating hiv-1 infection

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic